Financial conflict of interest may influence prescribing and messaging. The PMHNP should consider potential bias, the use of company-prepared materials, disclosure obligations, and professional integrity.
This is the correct answer. Pharmaceutical speaker bureau participation creates a financial conflict of interest that can influence the PMHNP's prescribing patterns and clinical messaging. Key concerns include financial incentives that may unconsciously bias medication recommendations, company-prepared slide decks and talking points that may present selectively favorable data, obligations to disclose financial relationships to patients and institutions under the Sunshine Act, and the impact on professional integrity and public trust in the provider's objectivity. Even well-intentioned clinicians are susceptible to the influence of financial relationships on clinical decision-making.